Achieving, Managing Patient Care During Maintenance Therapy for AML
The unique needs of patients with AML undergoing maintenance therapy, including care disparities and challenges, are discussed at the 2023 ONA Summit.
Diagnosis & Disease Information
CAR-T Cell Therapy Promising in Multiple Myeloma
Researchers sought to determine whether idecabtagene vicleucel, a CAR-T cell therapy, would be a viable treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
Chronic Health Conditions, Not Transplant Receipt, Linked to Symptom Prevalence in Survivors of Childhood Hematologic Malignancies
Survivors of childhood hematologic malignancies with poorly reported patient outcomes may have more chronic health conditions, regardless of treatment method.
Roles of Nurse Practitioner and Nurse Navigator in a CAR-T Therapy Program at a Large Academic Oncology Center
Hands-on roles initially played by nurse navigators and nurse practitioners in the delivery of CAR-T cell therapy have evolved into resource/care coordination roles.
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.
FDA approves ‘breakthrough therapy’ for CLL
Gazyva is designed to bolster the immune system’s ability to attack cancer cells.
Is there an occupational cancer risk with flying?
Has any research been conducted to determine whether the incidence of various types of skin cancer is greater in people who fly for a living compared with the general public?
Gleevec approved for pediatric acute lymphoblastic leukemia
Imatinib belongs to a class of drugs called tyrosine kinase inhibitors and blocks proteins that promote development of cancer cells.
Ponatinib wins early approval for rare leukemias
The FDA has approved ponatinib to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bosutinib approved for chronic myelogenous leukemia
The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are resistant to or who cannot tolerate other therapies.
- Loading...
Loading...
Next post in Web Exclusives
Loading... 
Loading...